Rights to Crohn's disease candidate returned to ChemoCentryx

09/19/2013 | Genetic Engineering & Biotechnology News

ChemoCentryx has regained all rights to the experimental drug vercirnon from GlaxoSmithKline following a late-stage trial. The drug failed to meet its main goal and an important secondary goal in the SHIELD-1 study of patients with moderately to severely active Crohn's disease. The move "confers to us many degrees of freedom in deciding this valuable asset's forward path," ChemoCentryx President and CEO Thomas J. Schall said.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care